Aurore ANDRE, CEO of Azapharm joins the strategic board of Apmonia Therapeutics, a biotechnology company dedicated to developing anti-cancer immunotherapy strategies.
Apmonia’s strategic board comprises experts in biotech, business, funding and more, who harness their experience to support the company’s innovation and growth.
“I am pleased to welcome Aurore to our strategic board. We believe the experience and knowledge she brings with her will contribute greatly to both our clinical and business development and growth”, said Albin JEANNE, CEO of Apmonia.
A while ago Apmonia announced a €2.5 million financing non-dilutive grant from Bpifrance, dedicated to completing the regulatory preclinical development of AP-01 drug candidate, an anti-cancer immunotherapy.